Cat. #162284
pBABE-hygro Vector
Cat. #: 162284
Unit size: Provided as 50-100ng cloning grade DNA on Whatman filter paper
Bacterial Resistance: Ampicillin
Selectable Markers: Hygromycin
£65.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Hartmut Land, Jay Morgenstern
Institute: Cancer Research UK London Research Institute: Lincoln's Inn Fields
Primary Citation: Morgenstern et al. 1990. Nucleic Acids Res. 18(12):3587-96. PMID: 2194165.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: pBABE-hygro Vector
- Research fields: Genetics
- Total vector size: 5558
- Backbone size without insert: 5558
- Bacterial resistance: Ampicillin
- Selectable markers: Hygromycin
- Description: High-titer retroviral empty backbone pBABE vector, ready for cloning. pBABE-hygro enables stable gene delivery and expression in mammalian cells with MO-MuLV LTR-driven expression for reliable, long-term transgene production. Features Hygromycin B selection useful for sequential selection studies. pBABE-hygro is a part of the established pBABE vector system, developed by Morgenstern and Land 1990. Key features include: high viral titers for efficient transduction, stable long-term gene expression via LTR promoter and helper-free design which minimises contamination risk.
- Additional notes: The pBABE vectors prove useful in experiments where highest frequencies of gene transfer, or concomitant expression of several different genes within a single cell are required with minimal risk of helper virus contamination.
Handling
- Shipping conditions: Provided as 50-100ng cloning grade DNA on Whatman filter paper
- Plasmid amplification details: DH5alpha 37° C
- Plasmid copy number: High copy
References
- Morgenstern et al. 1990. Nucleic Acids Res. 18(12):3587-96. PMID: 2194165. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)





